Headlines
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up
Published by Global Banking & Finance Review®
Posted on November 4, 2025
1 min readLast updated: January 21, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on November 4, 2025
1 min readLast updated: January 21, 2026
Novo Nordisk and Pfizer have raised their bids for Metsera, with Novo offering $10 billion and Pfizer $8.1 billion, amid legal disputes.
(Reuters) -Novo Nordisk and Pfizer have revised their bids for Metsera, the obesity drug developer said on Tuesday.
Novo's revised offer brings the deal value to about $10 billion, while Pfizer is now willing to shell out $8.1 billion.
The revised bids come as both companies are engaged in a public dispute to acquire Metsera.
Pfizer has filed two lawsuits against Metsera, its board, and Novo Nordisk.
The first lawsuit, filed on Friday, claims Novo's bid breaches Pfizer's merger agreement and seeks to bypass antitrust review. Pfizer is asking a court to block Metsera from terminating the deal, with a hearing set for later on Tuesday.
As per Novo's new offer, Metsera is also eligible to receive an additional $24.00 per share in cash, up from $22.50, based on development and regulatory approval milestones.
(Reporting by Mrinalika Roy, Christy Santhosh and Siddhi Mahatole in Bengaluru; Editing by Maju Samuel and Leroy Leo)
A merger is a business strategy where two companies combine to form a single entity, often to enhance competitiveness and operational efficiency.
An acquisition occurs when one company purchases another company, gaining control over its assets and operations.
Antitrust review is a legal examination of a merger or acquisition to ensure it does not create unfair competition or monopolistic practices.
Development milestones are specific goals or benchmarks in a project that, when achieved, can trigger additional funding or payments.
Explore more articles in the Headlines category
